Impact of adjuvant chemotherapy on the survival of patients with estrogen receptor ≥50 ％, human epidermal growth factor receptor-2 negative, lymph node negative breast cancer
10.3760/cma.j.issn.1007-631X.2018.03.012
- VernacularTitle:辅助化疗对ER≥50％、HER2阴性、淋巴结阴性乳腺癌生存的影响
- Author:
Wei CAO
1
;
Yingjian HE
;
Jinfeng LI
;
Tianfeng WANG
;
Yuntao XIE
;
Zhaoqing FAN
;
Tie FAN
;
Tao OUYANG
Author Information
1. 恶性肿瘤发病机制及转化研究教育部重点实验室
- Keywords:
Breast neoplasms;
Receptors,estrogen;
Receptors,epidermal growth factor;
Survival analysis
- From:
Chinese Journal of General Surgery
2018;33(3):223-227
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of adjuvant chemotherapy on the survival of patients with ER ≥ 50％,HER2 negative,lymph node negative breast cancer.Methods 428 patients from Jan 1,2004 to Dec 31,2010 were enrolled.All patients received operation plus chemoendocrine therapy (CET,n =239) or endocrine therapy (ET,n =189).Result The median follow-up time was 76.5 months,with 8.2％ loss to follow-up.The recurrence-free survival (RFS) was 93.7％ in CET group and 95.2％ in ET group,the distant disease-free survival (DDFS) was 94.6％ and 97.4％ in CET and ET group respectively.Multivariate regression indicated that the risk of tumor size ＞ 2 cm was higher than that of tumor size ≤2 cm in recurrence (HR=2.31,95％ CI 1.07-5.29,P =0.047) and metastasis (HR=4.71,95％ CI 1.47-11.85,P =0.01).Compared with CET group,however,no statistical significance was found on RFS (HR =1.08,95 ％ CI 0.46-2.57,P =0.86) and DDFS (HR =0.72,95 ％ CI 0.17-1.37,P =0.55) in ET group.Conclusions Adjuvant chemotherapy cannot improve the RFS and DDFS of ER≥50％,HER2 negative,lymph node negative breast cancer.Tumor size ＞ 2 cm was the risk factor of recurrence and distant metastasis.
